Literature DB >> 12748192

Phosphorylation of threonine 10 on CKBBP1/SAG/ROC2/Rbx2 by protein kinase CKII promotes the degradation of IkappaBalpha and p27Kip1.

Yun-Sook Kim1, Jae-Yong Lee, Mi-Young Son, Wan Park, Young-Seuk Bae.   

Abstract

In eukaryotic cells, protein kinase CKII is required for progression through the cell division cycle. We recently reported that CKBBP1/SAG/ROC2/Rbx2 associates with the beta-subunit of CKII and is phosphorylated by purified CKII in the presence of ATP in vitro. In this report, we demonstrate that CKBBP1 is efficiently phosphorylated in vitro by purified CKII in the presence of GTP and by heparin-sensitive protein kinase in HeLa cell extract. Mutational analysis indicates that CKII phosphorylates threonine at residue 10 within CKBBP1. Furthermore, CKBBP1 is phosphorylated in vivo and threonine to alanine mutation at residue 10 abrogates the phosphorylation of CKBBP1 observed in vivo, indicating that CKII is a major kinase that is responsible for in vivo phosphorylation of CKBBP1. As compared with the wild-type CKBBP1 or CKBBP1T10E (in which threonine 10 is replaced by glutamate), overexpression of nonphosphorylatable CKBBP1 (CKBBP1T10A) results in accumulation of IkappaBalpha and p27Kip1. Experiments using proteasome inhibitor MG132 and CKII inhibitor 5,6-dichloro-1-beta-d-ribofuranosylbenzimidazole suggest that the accumulation of IkappaBalpha and p27Kip1 results primarily from the reduction of proteasomal degradation in cells expressing CKBBP1T10A, and that CKII-mediated CKBBP1 phosphorylation is required for efficient degradation of IkappaBalpha and p27Kip1. Overexpression of CKBBP1T10A in HeLa cells suppresses cell proliferation and causes accumulation of G1/G0 peak of the cell cycle. Taken together, our results indicate that CKII may control IkappaBalpha and p27Kip1 degradation and thereby G1/S phase transition through the phosphorylation of threonine 10 within CKBBP1.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12748192     DOI: 10.1074/jbc.M302584200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  8 in total

1.  CK2 phosphorylation of SAG at Thr10 regulates SAG stability, but not its E3 ligase activity.

Authors:  Hongbin He; Mingjia Tan; Deepika Pamarthy; Guixia Wang; Khalil Ahmed; Yi Sun
Journal:  Mol Cell Biochem       Date:  2006-07-28       Impact factor: 3.396

2.  Specificity and regulation of casein kinase-mediated phosphorylation of alpha-synuclein.

Authors:  Elisa A Waxman; Benoit I Giasson
Journal:  J Neuropathol Exp Neurol       Date:  2008-05       Impact factor: 3.685

3.  Ability of CK2beta to selectively regulate cellular protein kinases.

Authors:  Birgitte B Olsen; Barbara Guerra
Journal:  Mol Cell Biochem       Date:  2008-06-17       Impact factor: 3.396

4.  Cdc34 C-terminal tail phosphorylation regulates Skp1/cullin/F-box (SCF)-mediated ubiquitination and cell cycle progression.

Authors:  Martin Sadowski; Amanda Mawson; Rohan Baker; Boris Sarcevic
Journal:  Biochem J       Date:  2007-08-01       Impact factor: 3.857

Review 5.  Functional characterization of SAG/RBX2/ROC2/RNF7, an antioxidant protein and an E3 ubiquitin ligase.

Authors:  Yi Sun; Hua Li
Journal:  Protein Cell       Date:  2012-11-08       Impact factor: 14.870

6.  How dietary arachidonic- and docosahexaenoic- acid rich oils differentially affect the murine hepatic transcriptome.

Authors:  Alvin Berger; Matthew A Roberts; Bruce Hoff
Journal:  Lipids Health Dis       Date:  2006-04-20       Impact factor: 3.876

7.  Expanding the substantial interactome of NEMO using protein microarrays.

Authors:  Beau J Fenner; Michael Scannell; Jochen H M Prehn
Journal:  PLoS One       Date:  2010-01-20       Impact factor: 3.240

8.  SAG/ROC2 E3 ligase regulates skin carcinogenesis by stage-dependent targeting of c-Jun/AP1 and IkappaB-alpha/NF-kappaB.

Authors:  Qingyang Gu; G Tim Bowden; Daniel Normolle; Yi Sun
Journal:  J Cell Biol       Date:  2007-09-10       Impact factor: 10.539

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.